SEC Tracker
Get the app

Camp4 Therapeutics CAMP

Camp4 Therapeutics reported a $28.96 million net loss

Form
10-Q
Filed
Importance
Notable
  1. Revenue of $1.9 million for the three months ended Sep 30, 2026
  2. Diluted EPS of -$0.37 for the three months ended Sep 30, 2026
  3. Cash and equivalents of $124.52 million as of Sep 30, 2026

Written from the 10-Q on EDGAR. AI can make mistakes. Check the filing.

Open in the appGet the appView on EDGAR

Get an email when Camp4 Therapeutics files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. X4 Pharmaceuticals XFOR public float $15M, Jun 30, 2025
  2. Akari Therapeutics AKTX public float $15M, Jun 30, 2025
  3. ProPhase Labs PRPH public float $15M, Jun 30, 2025
  4. Pluri PLUR public float $15M, Dec 31, 2025
  5. Edesa Biotech EDSA public float $14M, Mar 31, 2025, over 18 months old

Data on this page was fetched . The filing on SEC.gov is the record.